^NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, a
Biotechnology company that uses neural circuits to
Restoring immune homeostasis in diseases started today with a
$101M Series A Funding Led by The Column
Group (TCG), DCVC Bio and Lux Capital, with participation from the Gates Foundation
and Alexandria Venture Investments. At the same time as the market launch, Nilo
the appointment of Dr. Kim Seth as Chief Executive Officer and Board Member
announced.
Nilo was founded by the world’s leading scientists Dr. Charles Zuker
(Columbia University), Dr. Ruslan Medzhitov (Yale University) and Dr. Steve
Liberles (Harvard University) was founded in collaboration with TCG,
to bring groundbreaking scientific findings in neuroimmunology into new ones
implement therapeutic strategies. Dr. Seth will be with Chief
Scientific Officer Dr. Laurens Kruidenier the transformation of the company
guiding a stealth company into the next phase of growth. The financing
is used to set up Nilo’s laboratories in New York City and expand his
interdisciplinary research and development teams and further development
the company’s preclinical programs.
Nilo is developing drugs that use neural circuits to…
Centrally restore immune homeostasis. The company thus offers one
differentiated approach to immune modulation that goes beyond the traditional
Immunosuppression goes beyond. The company is based on groundbreaking
scientific discoveries from the laboratory of Dr. Charles Zuker
(Principal investigator at Columbia University and investigator at Howard Hughes Medical
Institute) who has identified certain vagal neurons that
regulate systemic immune activation and inflammation. Through the targeted
Influencing these central “master-regulator” circuits between the brain and
body, Nilo uses its novel therapeutic approach to target multiple immune pathways
to modulate at the same time, thereby reducing the risk of resistance to therapy
reduced and the potential effect on a broad spectrum of autoimmune
and inflammatory diseases with major unmet needs.
Dr. Seth has over 25 years of experience in the biopharma industry and
has held various leadership positions at several start-ups and
listed biotech companies and large pharmaceutical companies. He has
also comprehensive specialist knowledge in the areas of company structure and strategy
and R&D activities, business development, finance and capital markets. Before
During his time at Nilo, Dr. Seth as Chief Business Officer at Repare
Therapeutics, a precision oncology company. There
He was a member of the management team and played a key role in this
Companies from the pre-Series A financing round to the Series B
Scaling the financing round up to the IPO. He was for construction
of the company’s US business and led the
Business development to deliver across a range of global platforms, assets and
clinical partnerships have secured over $250 million in financing
generate a potential total value of over USD 4 billion.
Before working at Repare, Dr. Seth leadership positions in the
areas of business development, strategy and operations across a range of
biopharmaceutical companies, including Pfizer, and was a research analyst for large-scale
Cap pharmaceutical company/specialty pharmaceutical company at Goldman Sachs. He acquired
his BA cum laude in economics from Harvard College and his
PhD in Neurobiology in the Department of Medical Sciences at the
Harvard University.
Dr. Seth joins Dr. Laurens Kruidenier, Chief Scientific Officer, one
experienced experts in immunology and drug research. Dr.
Kruidenier previously served as CSO at Cellarity and Prometheus Biosciences (from Merck
taken over), where he developed several innovative therapies for autoimmune and
Advancing inflammatory diseases from concept to clinical application. To
Beginning his career at Takeda Pharmaceuticals and GSK, he led teams for
preclinical and discovery research and the strategy for
Business development. He received his doctorate in immunology from Leiden University
and his research results have been published in leading scientific publications
Published in specialist journals, including Nature.
“Nilo is in a phase of change,” says Dr. Laurens Kruidenier,
Chief Scientific Officer of Nilo Therapeutics.?The leadership qualities and
Experience of Dr. Seth will accelerate our mission, groundbreaking
Translating findings from neuroimmunology into medications
Patients with a variety of immune-related diseases benefit
could.”
“We are very pleased, Dr. “To be able to welcome Seth as CEO,” said Dr. Tim Kutzkey,
Managing Partner at The Column Group.?With his track record at
Supporting companies from their beginnings to their IPO and the
Successful implementation of programs brings Dr. Seth both foresight and
visions with. His passion, groundbreaking scientific findings
into innovative medicines makes him the ideal partner to help Laurens’
scientific leadership role and Nilo into the next one
to lead to a growth phase.”
“It is an honor to be part of the incredibly talented and dedicated team
of Nilo,” said Kim Seth, Chief Executive Officer of Nilo Therapeutics.
?Together with Laurens, our world-class scientific founders, and
For our investors, we are building a company that will inspire a new generation
Therapies will be developed that utilize the brain-immune axis to provide treatment
of autoimmune and inflammatory diseases.”
About Nilo Therapeutics
Nilo Therapeutics is a biotechnology company that is creating a new class of
Drugs are being developed that use neural circuits to…
To restore immune homeostasis in diseases. Through the targeted
Influencing the master regulatory circuits between the brain and body, the
To centrally control systemic inflammation, Nilo is doing pioneering work
differentiated approach to immunomodulation that has the potential to be broad
Spectrum of autoimmune and inflammatory diseases with major unmet needs
to treat. The company is headquartered in New York,
NY. www.nilotx.com (https://www.nilotx.com/)
For more information, contact [email protected]
(mailto:[email protected]).
°